(Q48180007)

English

Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. (English)

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

multiple sclerosis

0 references

cerebrospinal fluid

0 references

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

Carl V. Granger

10

object named as

Granger CV

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

author name string

Rudick RA

1

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Cookfair DL

2

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Simonian NA

3

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Ransohoff RM

4

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Richert JR

5

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Jacobs LD

6

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Herndon RM

7

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Salazar AM

8

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Fischer JS

9

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Goodkin DE

11

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Simon JH

12

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Bartoszak DM

13

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Bourdette DN

14

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Braiman J

15

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Brownscheidle CM

16

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Coats ME

17

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Cohan SL

18

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Dougherty DS

19

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Kinkel RP

20

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Mass MK

21

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Munchsauer FE

22

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

O'Reilly K

23

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Priore RL

24

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Whitham RH

25

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

publication date

1 January 1999

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Journal of Neuroimmunology

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

93

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

8-14

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

1-2

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900174-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900174-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysacchari

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900174-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The use and abuse of the cerebrospinal fluid IgG profile in the adult: a practical evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900174-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Intrathecal IgG synthesis and IgG index after intensive and chronic immunosuppressive treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900174-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900174-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900174-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900174-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunoglobulins in multiple sclerosis and infections of the nervous system.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900174-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900174-X

7 January 2021

based on heuristic

inferred from DOI database lookup

IL-10 stimulates murine antigen-driven antibody responses in vitro by regulating helper cell subset participation.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900174-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple sclerosis:cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900174-X

7 January 2021

based on heuristic

inferred from DOI database lookup

CSF oligoclonal bands, MRI, and the diagnosis of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900174-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Relative diagnostic value of cerebrospinal fluid kappa chains in MS: comparison with other immunoglobulin tests

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900174-X

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900174-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Sensitive competitive-binding ELISAs for quantifying free kappa and lambda light chains in cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900174-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900174-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900174-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple sclerosis de novo CNS IgG synthesis: effect of ACTH and corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900174-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900174-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0165-5728(98)00174-X

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

1 reference

Europe PubMed Central

9 February 2018

http://europepmc.org/abstract/MED/10378864

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48180007&oldid=1559598423"